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al mechanisms and immuno-epidemiologic implications are
onsidered.
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onitoring for avian inﬂuenza in wild birds on the Far East
n 2008
. Sayfutdinova1,∗, J. Runstadler2, M. Kulak1, M. Sivay3
State Research Center of Virology and Biotechnology
‘Vector’’, Koltsovo, Russian Federation
Institute of Arctic Biology, Fairbanks, AK, USA
State Research Center of Virology and Biotechnology ‘Vec-
or’, Koltsovo, Russian Federation
Background: Waterbirds are natural reservoirs for low-
athogenic avian inﬂuenza and have been implicated as the
rimary source of infection in outbreaks of highly pathogenic
vian inﬂuenza. An understanding of the movements of birds
nd the ecology of avian inﬂuenza viruses within the wild
ird population is essential in assessing the risks to human
ealth and production industries. The purpose of this inves-
igation was surveillance for avian inﬂuenza in migratory
horebirds at the East Asian-Australasian Flyway. Sample
ollection was on Kamchatka, on the Kuril islands, at the
mursky region, on Sakhalin and on Chukchi Peninsula.
Methods: Viral RNA was isolated from virus-containing
llantoic ﬂuid with the RNeasy Mini kit (QIAGEN, Valencia,
A, USA) as speciﬁed by the manufacturer. Uni12 primer was
sed for reverse transcription. PCR was performed with a
et of primers speciﬁc for each gene segment of inﬂuenza
virus (18). PCR products were puriﬁed with the QIAquick
CR puriﬁcation or QIAquick gel extraction kit (QIAGEN). The
mplicons were sequenced on an automated Applied Biosys-
ems 3130 system using BigDye terminator cycle sequencing
eady reaction kit» (Applied BioSystems).
Results: In the Far East in the 2008 from birds
f 127 spices and 32 families were collected 4248
amples and 16 inﬂuenza viruses were isolated and
nalyzed. No highly pathogenic avian inﬂuenza viruses
ere identiﬁed. The hemagglutinin genes of stains
/Larus/Kamchatka/521/08(H13N6) isolated in Kamchatka
egion and A/Teal/Tinda/6114/08(H10N6) (bankit1288867 in
enebank) isolated in Amursky region were analyzed genet-
cally. The analysis shows homology with the strains which
ere isolated in the Astrahansky region and on Hokkaido
sland.
Conclusion: Surveillance activities for avian inﬂuenza in
ild birds should be continued to provide further epidemio-
ogical information about circulating viruses and to identify
ny changes in subtype prevalence.This work was supported by Russian Government and Bio
ndustry Initiative (BII) USA (ISTC#3436) and was done in
ollaboration with Novosibirsk State University.
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.M. Velasco1, I.-K. Yoon1, D. Saunders1, A. Timmermans1,
. Ungchusak2, T. Wongstitwilairoong1, C.J. mason1, R.V.
ibbons1, J.A. Pavlin1,∗
Armed Forces Research Institute of Medical Sciences,
angkok, Thailand
Ministry of Public Health, Bangkok, Thailand
Background: On-going, comprehensive inﬂuenza surveil-
ance is critical to detect and monitor inﬂuenza outbreaks.
he Armed Forces Research Institute of Medical Sciences
AFRIMS) has established 45 inﬂuenza sentinel sites in
outh and Southeast Asia in 4 countries (Thailand, Nepal,
hilippines, Bhutan) and an additional 9 countries with par-
icipating US Embassies.
Methods: Patients who present with a history of fever
nd cough or sore throat can participate. Samples are tested
ith a rapid test for inﬂuenza A and B and realtime PCR for
nﬂuenza A (H1, pH1, H3, H5) and B. Some positive samples
ndergo virus isolation, characterization and sequencing at
FRIMS or in the US at the Centers for Disease Control and
revention (WHO Collaborating Center for Surveillance, Epi-
emiology and Control of Inﬂuenza).
Results: From October 2005 through September 2009,
FRIMS sites collected samples from 7,713 patients with
,239 taken since the H1N1 outbreak started in May 2009.
or the entire surveillance period, 42.2% of the samples
ere positive for inﬂuenza A or B by PCR. Since June 2009,
9.1% of the positive inﬂuenza samples have been pH1N1
ositive. Our surveillance system was the ﬁrst to detect
he presence of pH1N1 in Nepal and Bhutan. Evaluation of
nﬂuenza rapid tests compared to PCR differed by site but
ad overall 60% sensitivity and 97% speciﬁcity, and pH1N1
ad a 68% sensitivity and 98% speciﬁcity. Sequences from
ecent seasonal H1N1 viruses demonstrated greater than 97%
omology at the amino acid level with the 08/09 H1N1 vac-
ine strain. Samples from Bhutan and the Philippines had a
ery similar strain in circulation with 98.9-99.6% homology
t the amino acid level. A/Nepal/NP06C-017/2008 showed
he greatest divergence with the other strains (96.6-97.5%
omology). Seven pandemic H1N1 HA genes were sequenced
nd compared to other circulating viruses and were very sim-
lar. To date, all seasonal H1N1 and H3N2 viruses that have
een screened have genetic markers for M2 blocker resis-
ance and all pH1N1 demonstrate NA inhibitor resistance.
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Conclusion: An extensive inﬂuenza surveillance program
in Asia can document virus movement and genetic changes,
and is well positioned to provide assistance during pan-
demics and prevention efforts.
doi:10.1016/j.ijid.2010.02.2206
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H1N1 experience at the Institute for Infectious Diseases
Emilio Ribas, Sao Paulo, Brazil. The role of a travel clinic
as sentinel for emerging diseases
J. Alves, C.E. Guarnieri, T.S. Chaves ∗
Institute for Infectious Diseases Emilio Ribas, Sao Paulo,
Brazil
Background: According to WHO ﬁgures, by November 8
more than 503,536 cases of pandemic inﬂuenza had been
conﬁrmed and more than 6,260 deaths had been reported.
Most cases came from the Americas which also presented
the highest number of deaths. South America was severely
affected by the transmission of H1N1 and big efforts made to
control its dissemination and assist severe cases. Before July
16, when sustained transmission of pandemic inﬂuenza H1N1
was recognized in Brazil, most cases were travel related. By
late November, 22,565 cases had been reported in the coun-
try with a total of 1,528 deaths. The Institute for Infectious
Diseases Emilio Ribas (IIDER), a reference hospital for infec-
tious diseases in Sao Paulo city, was responsible for reporting
a signiﬁcant number of the entire state’s cases. As H1N1
was initially related to travelers, a number of patients were
referred to the clinic to be followed.
Methods: To evaluate the role of the travel clinic during
the ﬁrst months of the pandemic, we analyzed 53 report
care forms, broken down by gender, age, symptoms, history
of travel, diagnosis and treatment.
Results: Of the 53 patients evaluated, 21 were male
(39.6%) and 32 female (60.4%). The mean age was 38.7
and the most common symptoms were cough (90.5%), fever
(83%), headache (79%), coryza (64.1%), myalgia (73.5),
shortness of breath (49%) and diarrhea (16.9%). Oseltamivir
was prescribed to 35 (66%) of all patients. H1N1 was con-
ﬁrmed in 18 patients and Sazonal Inﬂuenza was isolated in
6 patients. Out of 17 patients who had traveled internation-
ally, only 3 tested positive for H1N1 and they had come from
Argentina (2) and Mexico (1).
Conclusion: Since the begining of the Inluenza pandemic,
IIDER had reported a total of 1,924 ﬂu-like cases by October
1, 2009. Because H1N1 transmission was initially associated
with travelers, travel clinics were able to provide ﬁrst warn-
ing. In our report, we include the ﬁrst case of H1N1 infection
in Sao Paulo city, a patient returning from Mexico who pre-
sented symptoms 2 days before the WHO global alert, which
demonstrates the high sensitivity of post-travel evaluations
in a pandemic scenario.
doi:10.1016/j.ijid.2010.02.2207
e
n
c
a
s
a
g
dts e323
5.010
s a mass immunization program for pandemic (H1N1)
009 good value for money? Early evidence from the
anadian experience
. Sander1,∗, C. Bauch2, R.A. Fowler3, D. Fisman1, J.
wong4, A. McGeer5, M. Zivkovic Gojovic6, M. Krahn1
University of Toronto, Toronto, ON, Canada
University of Guelph, Guelph, ON, Canada
Sunnybrook Health Sciences Center, Toronto, ON, Canada
Institute for Clinical Evaluative Sciences, Toronto, ON,
anada
Mount Sinai Hospital, Toronto, ON, Canada
York University, Toronto, ON, Canada
Background: Since the H1N1 vaccine approval on October
1, 2009 in Canada, the largest vaccination program in the
ountry’s history has been rolled out. This work contributes
nformed estimates to the current debate about the pan-
emic (H1N1) 2009 mass immunization program’s economic
erits.
Methods: We performed a cost-utility analysis of the
H1N1) 2009 mass immunization program in Ontario,
anada’s most populous province. We utilize a previ-
usly developed model to simulate the current pandemic
nﬂuenza (H1N1) outbreak in Ontario to compare no inter-
ention to mass immunization of 10% of the population
er week, starting 40 days into the pandemic and last-
ng until 30% vaccine coverage is reached. Data for health
are resource use (ofﬁce visits, emergency department vis-
ts, hospitalizations, intensive care unit admissions, use of
xtracorporeal membrane oxygenation (ECMO)) and deaths
ere based on pandemic (H1N1) surveillance data in Ontario
nd Australia, and Ontario administrative data. Program
nd other costs were drawn from Ontario sources (Ontario
ealth Insurance Plan (OHIP), Ontario Case Costing Initiative
OCCI)). Utility weights were obtained from the literature
nd annualized. Years of life lost were calculated using
verage life expectancy adjusted for quality of life. Main
utcome measures were quality adjusted life-years (QALYs),
osts in 2009 Canadian dollars, and cost per QALY gained.
Results: Ontario’s H1N1 immunization program is esti-
ated to cost $118 million ($30 per person vaccinated).
mmunizing 30% of the population prevents approximately
.4 million cases, 850 hospitalizations and 35 deaths. This
educes healthcare cost due to illness from $154 million to
77 million and is associated with 24,864 additional quality-
djusted life-years for the population. The incremental
ost-effectiveness ratio (ICER) is $1,645 per QALY gained.
esults are sensitive to immunization program effectiveness
nd cost. In all sensitivity analyses the ICER remains well
elow established thresholds, which determine the cost-
ffectiveness of a program.
Conclusion: The pandemic (H1N1) 2009 mass immu-
ization program in Ontario is highly costeffective under
onservative assumptions on health care resource use, costs,
nd mortality. This conclusion is supported by extensive
ensitivity analyses and is consistent with the economic
ttractiveness demonstrated for seasonal inﬂuenza pro-
rams.
oi:10.1016/j.ijid.2010.02.2208
